Aumolertinib effectively reduces clinical symptoms of an EGFR L858R-mutant non-small cell lung cancer case coupled with osimertinib-induced severe thrombocytopenia: a case report.

Abstract excerpt

Replacement of first-generation or second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) with third-generation EGFR-TKIs remains the current standard of care for T790M mutations in patients with non-small cell lung cancer. Osimertinib is one of the first third-generation EGFR-TKIs to be approved and is also the most widely studied in clinical research. There has been widespread...

Topics

• Female
• Humans
• Middle Aged
• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• ErbB Receptors
• Protein Kinase Inhibitors
• Mutation
• Aniline Compounds
• Thrombocytopenia